Retatrutide vs Semaglutide vs Tirzepatide: The Triple Agonist Compared

At a Glance

The incretin revolution moved through three generations in less than a decade. Where semaglutide set the benchmark for pharmacological weight loss in 2021, tirzepatide raised it substantially by adding GIP co-agonism, and retatrutide — Eli Lilly’s triple-receptor agent — now pushes further by engaging glucagon receptors as well. For clinicians and patients already navigating this landscape, the practical question is not which drug is newest, but which mechanism fits the individual’s metabolic profile, risk tolerance, and therapeutic goals.

How the Three Mechanisms Differ

Semaglutide: The GLP-1 Baseline

Semaglutide is a synthetic analogue of glucagon-like peptide-1 with a fatty acid side chain that extends its half-life to approximately seven days. By activating GLP-1 receptors in the hypothalamus, gut, and pancreas, it suppresses appetite, slows gastric emptying, and augments glucose-dependent insulin secretion. The STEP trials established 15–17% body weight reduction over 68 weeks in adults without diabetes — a figure that, at the time, represented a pharmacological ceiling.

Its cardiovascular benefit (SELECT trial, 20% reduction in MACE) and its utility in treating non-alcoholic steatohepatitis have solidified its position as the first-line agent for patients who need proven long-term data. For most practices, it remains the entry point into incretin therapy.

Tirzepatide: Adding GIP Co-Agonism

Tirzepatide targets both GLP-1 and GIP receptors simultaneously. The GIP component was initially counterintuitive — isolated GIP agonism in rodents sometimes promotes adipogenesis — but in combination with GLP-1 agonism, the net metabolic effect is amplified rather than attenuated. The SURMOUNT-1 trial showed 20.9% body weight loss at 72 weeks for the 15 mg dose, and SURMOUNT-4 demonstrated sustained results over two years.

Cardiovascular outcomes data from SURPASS-CVOT arrived in 2025, confirming a 15% MACE reduction comparable to semaglutide, which removed the key uncertainty that had slowed its adoption among cardiologists. Tirzepatide is now positioned as the preferred agent when both weight and glycaemic outcomes are prioritised together.

Retatrutide: The Glucagon Layer

Retatrutide adds glucagon receptor agonism to the GLP-1/GIP dual mechanism. Glucagon is classically understood as a counter-regulatory hormone that raises blood glucose and drives hepatic fatty acid oxidation. In the context of a triple agonist, glucagon receptor activation contributes additional energy expenditure, accelerated lipolysis, and — crucially — further appetite suppression through central mechanisms that are additive to GLP-1 signalling.

The Phase 2 GZGI trial published in the New England Journal of Medicine in 2023 showed 24.2% body weight reduction at 48 weeks for the 12 mg dose in adults with obesity. Phase 3 trials completed enrolment in 2025, with an NDA submission anticipated by late 2026. No head-to-head data between retatrutide and tirzepatide exist yet; the comparison in this article is indirect, based on separate trial populations and endpoints.

Weight Loss Depth: Reading the Numbers Honestly

The headline figures — 15%, 22%, 24% — require important context before clinical application:

Trial populations differ. STEP 1 (semaglutide) enrolled adults with BMI ≥30, average baseline weight ~105 kg. SURMOUNT-1 (tirzepatide) had a similar profile. GZGI (retatrutide) enrolled a slightly higher-weight cohort at average ~106 kg but with a shorter 48-week window — extrapolation to 72 weeks would likely close some of the apparent gap.

Responder rates matter more than means. In GZGI Phase 2, approximately 26% of patients on 12 mg retatrutide lost more than 30% of body weight. For comparison, roughly 10% of STEP 1 participants achieved that threshold. The distribution of response, not just the average, is what determines whether a given patient is likely to benefit from escalating therapy.

What happens to lean mass? All three agents cause some loss of lean tissue alongside fat mass. In STEP 1, roughly 38% of lost weight was lean tissue — a figure that tracks with other very-low-calorie interventions. Tirzepatide data suggests a slightly more favourable fat-to-lean ratio. Retatrutide has not yet published detailed body composition data from Phase 3. Glucagon receptor agonism increases protein catabolism as a first-principles concern, making the lean mass question the most critical unknown for retatrutide in clinical practice.

Muscle Preservation: The Critical Clinical Gap

For patients who present with pre-existing sarcopenia, older adults, or athletes, the lean mass trajectory under each agent is the primary differentiating factor — not weight loss percentage.

Under semaglutide and tirzepatide, current evidence supports aggressive resistance training plus protein intake of 1.6–2.2 g/kg ideal body weight as effective mitigation. In patients who follow this protocol, lean mass loss can be reduced to under 20% of total weight lost.

With retatrutide, the glucagon component introduces theoretical additional muscle catabolism risk. Until Phase 3 body composition data are published, this cannot be confirmed or refuted. My clinical practice will not offer retatrutide to patients with BMI-adjusted skeletal muscle index below the 25th percentile until those data exist. For well-nourished, physically active patients with significant adiposity, the risk calculus changes.

Adjunct peptides with anabolic or muscle-sparing properties — including BPC-157 for connective tissue recovery and growth hormone secretagogues such as ipamorelin-CJC-1295 — are increasingly being used alongside GLP-1 class agents in integrative practices. This is an off-label combination with no formal safety data; each case must be evaluated individually.

Who Is Each Agent For?

Choose semaglutide when:

• First-line therapy is indicated and the patient has no prior incretin exposure
• Cardiovascular risk reduction is the co-primary goal (SELECT data is unique to semaglutide)
• Long-term safety and post-marketing data are a priority for a risk-averse patient
• Cost or insurance coverage favours a more established agent

Choose tirzepatide when:

• Semaglutide response was sub-therapeutic (< 10% weight loss at 6 months on maximum tolerated dose)
• T2DM is present and glycaemic optimisation matters alongside weight
• The patient has demonstrated capacity to tolerate GLP-1 class side effects
• Cardiovascular outcomes data (SURPASS-CVOT) are acceptable as a basis for treatment

Consider retatrutide (once approved) when:

• Tirzepatide produced meaningful but insufficient response
• Metabolic syndrome is severe — hepatic steatosis grade 2–3, multiple components of insulin resistance
• The patient is physiologically young, musculoskeletally robust, and motivated to preserve lean mass through training
• No Phase 3 safety signals have emerged that materially change the risk-benefit assessment

Retatrutide is not, at this stage, appropriate as a first-line agent. Its role in a sequenced treatment algorithm is as a third-tier option for patients who have genuinely exhausted earlier-tier options, not a substitute for them.

Side Effects and Tolerability

All three agents share a common GI side effect profile driven by GLP-1 receptor activity: nausea, vomiting, diarrhoea, and constipation, predominantly during dose escalation. Serious adverse events are rare but include acute pancreatitis, gallstone disease, and — a concern that remains under investigation — thyroid C-cell effects (a class signal from rodent studies not confirmed in human registries).

Retatrutide adds a hypoglycaemia risk that is theoretically lower than with insulin but potentially amplified compared with semaglutide or tirzepatide when used alongside other glucose-lowering medications, because glucagon suppression removes one counter-regulatory buffer. Patients on sulfonylureas or basal insulin will require dose reduction planning before initiating retatrutide.

The Phase 2 data showed discontinuation due to adverse events at approximately 16% for the 12 mg dose — higher than the ~9% seen with tirzepatide 15 mg. Whether optimised titration schedules in Phase 3 narrow this gap will be important for commercial uptake.

Switching and Sequencing Between Agents

Patients moving from semaglutide to tirzepatide need a washout consideration if switching during active dose titration; most clinical protocols start tirzepatide at the lowest dose (2.5 mg) regardless of prior semaglutide dose to allow receptor reset.

The equivalent question for tirzepatide to retatrutide transitions has not been studied. Based on receptor pharmacology, a conservative approach — washout of 4–8 weeks, then retatrutide initiation at lowest available dose with extended up-titration — seems prudent until clinical data exist.

Cycling down from retatrutide to tirzepatide or semaglutide for maintenance may become a clinically important strategy if the metabolic depth achieved with retatrutide can be sustained at lower receptor load. This requires empirical study.

Related Articles

• Semaglutide vs Tirzepatide: Head-to-Head Clinical Comparison
• Semaglutide for Weight Loss: What the Evidence Actually Shows
• Muscle Preservation on GLP-1 Therapy: Protocol for Athletes and Active Patients (coming soon)
• Preserving Muscle on Semaglutide and Tirzepatide: Diet and Exercise Protocol
• Peptide Therapy for Women: Hormonal and Metabolic Considerations
• Berberine vs Semaglutide: Mechanisms, Evidence, and Clinical Fit

References

1. Jastreboff AM et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.” Lancet. 2023;402(10401):529-544. PMID: 37385275
2. Jastreboff AM et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023;389(6):514-526. PMID: 37385281
3. Jastreboff AM et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387(3):205-216. PMID: 35658024
4. Wilding JPH et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
5. Lincoff AM et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131
6. Garvey WT et al. “Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.” Nat Med. 2022;28(10):2083-2091. PMID: 36216945
7. Rubino DM et al. “Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.” JAMA. 2022;327(2):138-150. PMID: 35015112